Genomic aberrations of the PTEN tumour suppressor gene are among the most common in
prostate cancer. Inactivation of PTEN by deletion or mutation is identified in∼ 20% of …

The development of targeted therapies has revolutionized cancer treatment, offering
improved efficacy with reduced side effects compared with traditional chemotherapy. This …

Purpose: Chemerin (retinoic acid receptor responder 2, RARRES2) is an endogenous
leukocyte chemoattractant that recruits innate immune cells through its receptor, ChemR23 …

Prostate carcinoma is one of the most prevalent cancers worldwide. Multiparametric
magnetic resonance imaging (mpMRI) is a non-invasive tool that can improve prostate …

While organ‐confined prostate cancer (PCa) is mostly therapeutically manageable,
metastatic progression of PCa remains an unmet clinical challenge. Resistance to anoikis, a …

Background Active surveillance (AS) is an option for men with low-risk prostate cancer
(PCa). PTEN and ERG have been considered as potential biomarkers of PCa progression …

Abstract Caveolin-1 (CAV1) is over-expressed in prostate cancer (PCa) and is associated
with adverse prognosis, but the molecular mechanisms linking CAV1 expression to disease …

Background Prostate cancer (PCa) with loss of the tumor suppressor gene PTEN has an
unfavorable prognosis. DNA methylation profiles associated with PTEN loss may provide …

Background Tumor stroma associates with prostate cancer (PCa) progression, but its
specific cellular composition and association to patient survival outcome have not been …

Genomic instability is one of the hallmarks of cancer. The incidence of genetic alterations in
homologous recombination repair genes increases during cancer progression, and 20% of …